It amazes me at how the market can value the potentialof some...

It amazes me at how the market can value the potential
of some companies so highly, and others at the other end of the scale.

Chemeq is capped at abt 291 mill. Uni is capped at 70 mill but Bioprospect is only capped at 8 mill.

Bioprospect has just has much chance as others as
being successful with there product.

The results of the Qcide trial by Nufarm should be
avaliable shortly and hopefully Sumitomo's not long
after.

If the trials are a success Bpo has the chance to make
as much or more than Cmq and Uni.